Abstract library

25 results for "seer".
#318 The SEER as a Prophet: Epidemiological Analysis as a Harbinger of Evolving Priorities in Gastroenteropancreatic Neuroendocrine Neoplasia
Introduction: Previous epidemiology analysis of tumor registries established that gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs) were both more prevalent, and more malignant, than previously recognized.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Mark Kidd
#1634 Trends of Incidence and Survivals for Gastric Neuroendocrine Neoplasms: An Analysis of 3523 Patients in the SEER Database
Introduction: The published evidence on gastric neuroendocrine neoplasms (g-NENs) is often based on small series of patients.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Huang Chang-Ming
#500 Duodenal Carcinoid Tumors are Associated with Increased Survival and Earlier Detection When Compared with Jejunal or Ileal Carcinoids: A Population Based Study
Introduction: Seventy to eighty percent of small intestinal carcinoids (SIC) are found incidentally. Jejunal and ileal lesions can often be resected locally, but advanced duodenal carcinoids require high-risk pancreaticoduodenectomy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Sunil Amin
Authors: Amin S, Kim M, Frucht H, ...
#1783 Gastroenteropancreatic High-Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 6291 Cases
Introduction: Knowledge about gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) is scarce given their low incidence rates and aggressive clinical behavior
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Arvind Dasari
Authors: Dasari A, Mehta K, Sorbye H, Yao J C, ...
Keywords: Grade 3, NE carcinoma
#1459 Does Faecal Occult Blood Testing Help Identify Ileo-Colonic NETs in the UK Bowel Cancer Screening Programme (BCSP)?
Introduction: There has been an increase in the incidence of ileo-colonic NETs in recent years, partly from endoscopy. There is no published data on the incidence of NETs diagnosed in the UK ‘double’ screen BCSP of initial Faecal Occult Blood stool test (FOBt) and, if abnormal, colonoscopy. The incidence (per 100k) of colorectal cancer (CRC) in FOBt abnormal UK BCSP colonoscopy is 55 times that of the population incidence (10k vs 184).
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Ron Basuroy
#385 Treatment of Small Bowel Neuroendocrine Tumor (NETS): A Single Center's Experience
Introduction: Neuroendocrine tumors (NETS) of the gastrointestinal tract are rare, slow-growing neoplasms. Long-term management of these tumors varies among centers.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
Keywords: survival
#1484 Neuroendocrine Tumors of the Appendix Are Probably Harmless Neoplasms
Introduction: Appendiceal neuroendocrine tumors (aNETs) have a 5-year survival rate between 74% and 95% according to recent data from Cancer Registry of Norway and the United States, respectively. However, in the daily clinical practice one almost never encounters patients suffering from aNETs with distant metastasis or dying of the disease.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Maike Nieser
Keywords: NET
#1771 Nomogram Individually Predicts the Overall Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: A few previous studies have shown that nomograms can predict the survival rates of patients with neuroendocrine neoplasms (NENs).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Wang Wei
Authors: Wei W, Cheng F, Jie C, Zhiwei Z, ...
#2005 Incidence and Prevalence of Neuroendocrine Tumors in England
Introduction: Historically the incidence and prevalence of neuroendocrine tumours (NETs) has been difficult to establish. Studies by Ellis et al in 2006 estimated the incidence of gastroenteropancreatic neuroendocrine tumours (GEP NETs) to be 1.3 per 100,000 per year (incidence hereafter given as cases per 100,000). However, the SEER USA data suggests a four-fold higher incidence, and prevalence of 35 per 100,000.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tracey Genus
#141 Incidence of second primary tumors in patients with neuroendocrine tumors
Introduction: Based on epidemiological data from SEER 1950-1999, 22.4% cases of non-carcinoid second primary tumors have been described in patients diagnosed with neuroendocrine tumors. The incidence of this type of tumors varies, depending on the series assessed.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Juan Manuel OConnor
Authors: Pesce V, OConnor J, Mendez G, Bestani C, ...